Contact Us
Drug Search Results
More Filters [+]

WTX-212

Alternative Names: WTX-212, WTX 212, WTX212, WTX 212A, WTX212A
Latest Update: 2025-01-16
Latest Update Note: Clinical Trial Update

Product Description

WTX212 is an erythrocyte-anti-PD1 antibody conjugate under development by Westlake Therapeutics. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e14529?af=R)

Mechanisms of Action: PD-1 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for WTX-212

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Reboot-102

P1

Recruiting

Oncology Solid Tumor Unspecified

2026-08-30

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions